Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Earth BioGenome Project Seeks to Sequence Planet's Eukaryotic Species

Earth BioGenome Project Seeks to Sequence Planet's Eukaryotic Species

Mar 16, 2017
|
Christie Rizk
Premium

NEW YORK (GenomeWeb) – How much time and money would it take to sequence the genomes of 9,000 eukaryotic families, 150,000 to 200,000 genera, and 1.5 million species?

The answer, according to organizers of the Earth BioGenome Project (EBP), is about 10 years and roughly $4 billion. The attempt to sequence all eukaryotic species on Earth has been likened by its coordinators to the Human Genome Project (HGP), both in its ambitions and for the benefits they hope it will bring to biological research.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Analysis for the Long Term

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Pricey, But Available

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Pilot Cancer Testing Program for Taiwan

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

PLOS Papers on TB Resistance, Squamous Cell Carcinoma Risk, MicroRNAs in SCC

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

What's Popular?

In Sequencing

  1. CRISPR Screens Identify Host Factors Required for SARS-CoV-2 Infection

  2. FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

  3. Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

    Premium

  4. At AGBT, Two Labs Share SARS-CoV-2 Genomic Surveillance Experience

    Premium

  5. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.